Carlyle and Viyash Life Sciences today announced that the two have established an integrated generic pharmaceutical platform in India.
In a statement, Carlyle said that Viyash is a leading manufacturer of Active Pharmaceutical Ingredients (API) intermediates with a strategy to consolidate other pharma intermediates, API and formulation assets to create an integrated offering for large generics customers.
The statement notified that Carlyle commenced its partnership with Viyash in June 2021, when the company acquired a controlling stake in Symed Labs, a leading manufacturer of niche APIs to enable backward integration. Viyash has also acquired a controlling stake in Appco Pharma LLC, the US, a formulations player focussed on the US market, which will help expand access to the US generics market and formulation capabilities.
Dr Hari, CEO, Viyash platform, commented, “We are delighted to partner with Carlyle at this exciting time for the Indian pharma industry. Viyash will focus on providing global formulation players with end-to-end manufacturing capabilities. Our next phase will be to drive further integration and growth opportunities across the three businesses.”
Adding to it, Dr Srihari, COO of the integrated platform, said, “Carlyle’s global healthcare expertise and network of portfolio companies, coupled with our industry knowledge and experience, will help us create significant value for the platform.”